Data Availability Statement No new data were created
Key Considerations: A Summary Table The Bottom Line: A Partnership with Your Doctor Choosing between semaglutide tablets and injections is a personal decision best made in conjunction with your physician
In March 2026, the first phase III clinical study (HS-20094-301) of olepotide in overweight or obese adult subjects in China achieved its primary endpoint
4D) is also shown for transparency
Because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency, reliability, or to establish a causal relationship to drug exposure
Foundayo, another oral GLP-1 option, and Zepbound, a dual hormone approach, diversify your treatment choices, enhancing weight loss outcomes